Rosacea Concierge Sets the Bar for Patient Support
with Unique Resources
Revamped website, mobile app and 24/7 support for
people living with rosacea
WHIPPANY, NJ, September 24, 2013 /PRNewswire/ — Rosacea Concierge, a one-of-a-kind resource for the estimated 16 million people living with rosacea1, has been launched by Bayer HealthCare. The new, easy-to-navigate www.RosaceaConcierge.com includes information on rosacea in the form of video tutorials from a team of experts, including a dermatologist, nutritionist and an aesthetician who offer perspectives and recommendations covering many aspects of living with rosacea.
In addition to online services, the Rosacea Concierge program also offers access to a 24-hour Rosacea Concierge support line staffed by nurses who specialize in rosacea education and a custom mobile application, www.TheRosaceaApp.com. Both the support line and the application help patients get “in the know” by providing access to the latest news, tips and tools for understanding rosacea. Rosacea Concierge and The Rosacea App are not intended to be a substitute for medical care. Bayer encourages patients to visit their healthcare professional for proper diagnosis and advice on treatment options.
Rosacea is a common skin disease that mainly affects the nose, cheeks, chin, and forehead.2 The condition usually affects people between 30 and 50 years of age, and tends to be more common in those with fair complexions. While more women than men are diagnosed with rosacea, the symptoms tend to be more severe in men.3
By registering for Rosacea Concierge, patients will be able to:
- Speak “live” with nurses specializing in rosacea education
- Watch videos with information about rosacea from experts in dermatology, nutrition and aesthetics such as advice for handling flare-ups, make-up advice and diet and exercise tips
- Access personalized online tools and a variety of other helpful resources such as medication refill reminders and a trigger tracker
- Print copay cards to help cover the cost of purchasing medication
"I have been involved with the Rosacea Concierge program from the very beginning, and the updates to the website are just fantastic,” said Dr. Julie Harper, private practice, Dermatology and Skin Care Center of Birmingham, partnering with Bayer on the Rosacea Concierge program. "While Rosacea Concierge is not a substitute for medical care, for many people living with rosacea it is a great resource for information that now has even more to offer.”
To enroll, visit www.RosaceaConcierge.com or call 1-855-346-2232.
INDICATION & USAGE
Finacea® (azelaic acid) Gel, 15% is a topical prescription medication used to treat inflammatory papules (raised spots) and pustules (pimple-like bumps) of mild to moderate rosacea. Although Finacea® does reduce some redness when raised spots and pimple-like bumps are present, Finacea® has not been studied for treating people with only redness from rosacea.
IMPORTANT SAFETY INFORMATION
Skin irritation (e.g., itching, burning or stinging) may occur during use with Finacea®, usually during the first few weeks of treatment. If sensitivity or severe irritation develops and persists during use with Finacea®, discontinue use and call your doctor for treatment.
Report abnormal changes in skin color to your doctor. There have been isolated reports of loss of skin color (a condition called hypopigmentation) after use of Finacea®. If you have a dark complexion, your doctor will monitor you for early signs of loss of skin color.
Avoid contact with the eyes, mouth or mucous membranes. In case of accidental eye exposure, wash eyes with large amounts of water and consult a physician if eye irritation persists. Wash hands immediately following application of Finacea®.
Avoid use of alcoholic cleansers, solutions, and astringents, abrasives and peeling agents while using Finacea®. Avoid the use of tight dressings or wrappings after using Finacea®.
The most common adverse reactions for Finacea® are: burning, stinging, or tingling of the skin, itching, dry or scaling skin, and skin irritation or redness.
Use only as directed by your physician. Finacea® is for topical use only. It is not for ophthalmic, oral or intravaginal use. Your healthcare provider will reassess you if no improvement is seen upon completing 12 weeks of therapy.
See full Prescribing Information for Finacea®.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.
- National Rosacea Society. “Rosacea Riddle Now Threatens More Than 16 Million Americans”. Press release issued April 1, 2010. http://www.rosacea.org/press/archive/20100401.php. Accessed on March 19, 2013.
- Web MD. “Rosacea Topic Overview.” http://www.webmd.com/skin-problems-and-treatments/tc/rosacea-topic-overview. Accessed on March 19, 2013.
- American Academy of Dermatology. “Rosacea: Who gets and causes”. http://www.aad.org/dermatology-a-to-z/diseases-and-treatments/q—-t/rosacea/who-gets-causes. Accessed on March 19, 2013
Anne Coiley, (862) 404-4607
Lora Grassilli, (212) 614-4018
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.